Current insights on the risk of thrombogenicity with off-label use of rFVlla.
Key
Nigel
N
Division of Hematology, University of North Carolina, Chapel Hill, NC, USA.
D000368:Aged; D005167:Factor VII / Q000009:adverse effects* / Q000627:therapeutic use; D015942:Factor VIIa; D005260:Female; D006801:Humans; D020300:Intracranial Hemorrhages / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012307:Risk Factors; D013927:Thrombosis / Q000139:chemically induced* / Q000209:etiology
D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa